Article

Challenging the intervertebral disk degeneration paradigm

Traditionally recognized factors, such as age and biomechanics (abnormal physical loading), may play a role in the manifestation of intervertebral disk degeneration, according to researchers in the department of orthopaedics & traumatology at the University of Hong Kong. However, additional factors also may contribute.

Traditionally recognized factors, such as age and biomechanics (abnormal physical loading), may play a role in the manifestation of intervertebral disk degeneration, according to researchers in the department of orthopaedics & traumatology at the University of Hong Kong. However, additional factors also may contribute.

Cheung and colleagues1 studied the prevalence of and risk factors associated with a unique pattern of disk degeneration of the lumbar spine, “skipped” level (nonconsecutive) disk degeneration (SLDD). To do so, they performed a cross-sectional analysis of participants in a large genetic-based study with disk degeneration of more than 2 levels, who were placed in SLDD and non-SLDD groups. Various radiographic parameters were evaluated on the basis of T2-weighted MRI; demographics also were assessed.

SLDD was present in 8.7% and 20.8% of the overall and multilevel disk degeneration populations, respectively; it was more prevalent in men. The condition was significantly associated with the presence of Schmorl nodes, also seen in levels with no disk degeneration. Disk bulge and extrusion and history of back injury were significantly associated with non-SLDD; a greater degree of overall disk degeneration severity also was associated with non-SLDD.

The authors noted that their study may be the first to describe the prevalence of SLDD and risk factors associated with it and that the additional factors warrant further investigation.

 

 

References:

1.

Cheung KM, Samartzis D, Karppinen J, et al. Intervertebral disc degeneration: new insights based on “skipped” level disc pathology.

Arthritis Rheum.

2010 Apr 19; [Epub ahead of print].

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.